Neumora Therapeutics, Inc. Common Stock
General ticker "NMRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $378.3M (TTM average)
Neumora Therapeutics, Inc. Common Stock does not follow the US Stock Market performance with the rate: -21.1%.
Estimated limits based on current volatility of 6.0%: low 0.95$, high 1.07$
Factors to consider:
- Total employees count: 96 (-12.7%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operating losses, Failure to achieve profitability, Funding requirements, Clinical trial delays, Regulatory and compliance
- Current price 32.6% below estimated low
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.23$, 3.56$]
- 2026-12-31 to 2027-12-31 estimated range: [1.17$, 3.35$]
Financial Metrics affecting the NMRA estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: 49.86 < Shareholder equity ratio, % of 54.37 <= 58.56
- Positive: Interest expense per share per price, % of 1.10 <= 1.42
- Positive: Investing cash flow per share per price, % of 57.80 > 2.08
- Positive: Inventory ratio change, % of 0 <= 0
Short-term NMRA quotes
Long-term NMRA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $252.10MM | $263.46MM | $241.16MM |
| Operating Income | $-252.10MM | $-263.46MM | $-241.16MM |
| Non-Operating Income | $16.44MM | $19.86MM | $4.36MM |
| Interest Expense | $0.00MM | $0.00MM | $3.22MM |
| R&D Expense | $206.62MM | $200.93MM | $181.06MM |
| Income(Loss) | $-235.66MM | $-243.61MM | $-236.80MM |
| Taxes | $0.27MM | $0.18MM | $0.13MM |
| Net Income(Loss)* | $-235.93MM | $-243.79MM | $-236.93MM |
| Stockholders Equity | $469.08MM | $287.06MM | $103.87MM |
| Assets | $496.19MM | $316.97MM | $191.05MM |
| Operating Cash Flow | $-163.28MM | $-182.94MM | $-206.44MM |
| Capital expenditure | $0.12MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $64.39MM | $-70.56MM | $168.52MM |
| Financing Cash Flow | $231.94MM | $21.60MM | $77.09MM |
| Earnings Per Share** | $-1.49 | $-1.53 | $-1.45 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.